Cargando…

Binding Adaptation of GS-441524 Diversifies Macro Domains and Downregulates SARS-CoV-2 de-MARylation Capacity

Viral infection in cells triggers a cascade of molecular defense mechanisms to maintain host-cell homoeostasis. One of these mechanisms is ADP-ribosylation, a fundamental post-translational modification (PTM) characterized by the addition of ADP-ribose (ADPr) on substrates. Poly(ADP-ribose) polymera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsika, Aikaterini C., Gallo, Angelo, Fourkiotis, Nikolaos K., Argyriou, Aikaterini I., Sreeramulu, Sridhar, Löhr, Frank, Rogov, Vladimir V., Richter, Christian, Linhard, Verena, Gande, Santosh L., Altincekic, Nadide, Krishnathas, Robin, Elamri, Isam, Schwalbe, Harald, Wollenhaupt, Jan, Weiss, Manfred S., Spyroulias, Georgios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284540/ https://www.ncbi.nlm.nih.gov/pubmed/35839840 http://dx.doi.org/10.1016/j.jmb.2022.167720

Ejemplares similares

(1)H,(13)C and (15)N chemical shift assignments of the SUD domains of SARS-CoV-2 non-structural protein 3c: “the N-terminal domain-SUD-N”
por: Gallo, Angelo, et al.
Publicado: (2020)

(1)H,(13)C and (15)N chemical shift assignments of the SUD domains of SARS-CoV-2 non-structural protein 3c: “The SUD-M and SUD-C domains”
por: Gallo, Angelo, et al.
Publicado: (2021)

NMR study of macro domains (MDs) from betacoronavirus: backbone resonance assignments of SARS–CoV and MERS–CoV MDs in the free and the ADPr-bound state
por: Tsika, Aikaterini C., et al.
Publicado: (2021)

Pharmacokinetics of Orally Administered GS-441524 in Dogs
por: Yan, Victoria C., et al.
Publicado: (2021)

Practical and Highly Efficient Synthesis of Remdesivir from GS-441524
por: Hu, Tianwen, et al.
Publicado: (2022)

NMR study of human macroPARPs domains: (1)H, (15)N and (13)C resonance assignment of hPARP14 macro domain 2 in the free and the ADPr bound state
por: Fourkiotis, Nikolaos K., et al.
Publicado: (2022)

(1)H, (13)C, and (15)N backbone chemical shift assignments of the apo and the ADP-ribose bound forms of the macrodomain of SARS-CoV-2 non-structural protein 3b
por: Cantini, F., et al.
Publicado: (2020)

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
por: Amirian, E. Susan, et al.
Publicado: (2020)

An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir
por: Moorthy, Ramkumar, et al.
Publicado: (2021)

Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
por: Leegwater, E., et al.
Publicado: (2022)

Exploration of the optimal GS-441524 trough concentration for treating COVID-19
por: Nakano, Yuki, et al.
Publicado: (2023)

Transplacental transfer of Remdesivir and GS‐441524: An ex vivo perfusion study
por: Louchet, Margaux, et al.
Publicado: (2023)

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
por: Yan, Victoria C., et al.
Publicado: (2020)

Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2
por: Wei, Daibao, et al.
Publicado: (2021)

Synthesis and anti-SARS-CoV-2 activity of deuterated GS-441524 analogs
por: Zheng, Wei, et al.
Publicado: (2022)

Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2021)

Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524
por: Krentz, Daniela, et al.
Publicado: (2021)

In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus
por: Doki, Tomoyoshi, et al.
Publicado: (2022)

Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats
por: Yang, Ling, et al.
Publicado: (2022)

Backbone and side chain NMR assignment of the heme-nitric oxide/oxygen binding (H-NOX) domain from Nostoc punctiforme
por: Chasapi, Styliani A., et al.
Publicado: (2022)

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
por: Pedersen, Niels C, et al.
Publicado: (2019)

Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
por: Lê, Minh Patrick, et al.
Publicado: (2020)

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021)

Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis
por: Jones, Sarah, et al.
Publicado: (2021)

Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2022)

Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects
por: Tempestilli, Massimo, et al.
Publicado: (2022)

Quantification of GS-441524 concentration in feline plasma using high performance liquid chromatography with fluorescence detection
por: Kimble, Benjamin, et al.
Publicado: (2023)

MARTs and MARylation in the Cytosol: Biological Functions, Mechanisms of Action, and Therapeutic Potential
por: Challa, Sridevi, et al.
Publicado: (2021)

Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain
por: Ni, Xiaomin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction
por: Sukeishi, Asami, et al.
Publicado: (2021)

Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection
por: Pitts, Jared, et al.
Publicado: (2022)

Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
por: Xie, Jiashu, et al.
Publicado: (2021)

Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment
por: Wang, Amy Q., et al.
Publicado: (2022)

NMR study of a soluble Guanylate Cyclase (sGC) human homologue: the H-NOX domain from Nostoc sp.
por: Argyriou, Aikaterini, et al.
Publicado: (2015)

Antiviral treatment using the adenosine nucleoside analogue GS‐441524 in cats with clinically diagnosed neurological feline infectious peritonitis
por: Dickinson, Peter J., et al.
Publicado: (2020)

Fecal Feline Coronavirus RNA Shedding and Spike Gene Mutations in Cats with Feline Infectious Peritonitis Treated with GS-441524
por: Meli, Marina L., et al.
Publicado: (2022)

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
por: Wang, Zhonglei, et al.
Publicado: (2022)

Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses
por: Zhou, Qifan, et al.
Publicado: (2023)

Thirty‐two cats with effusive or non‐effusive feline infectious peritonitis treated with a combination of remdesivir and GS‐441524
por: Green, Jodie, et al.
Publicado: (2023)

Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies
por: Xiao, Deqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gstqqp1nhcl8hp1d1l3nejsjut